Fulcrum Therapeutics, Inc. (FULC) News & Info.

#ThinkSabio Latest News

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
FULC fails FSHD P3.